X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs LUPIN LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA LUPIN LTD SANOFI INDIA/
LUPIN LTD
 
P/E (TTM) x 38.2 28.5 133.9% View Chart
P/BV x 7.2 2.7 263.8% View Chart
Dividend Yield % 0.5 0.6 86.7%  

Financials

 SANOFI INDIA   LUPIN LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
LUPIN LTD
Mar-18
SANOFI INDIA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs4,9451,465 337.5%   
Low Rs3,901727 536.5%   
Sales per share (Unadj.) Rs1,081.8349.6 309.5%  
Earnings per share (Unadj.) Rs141.65.6 2,546.9%  
Cash flow per share (Unadj.) Rs185.929.6 628.6%  
Dividends per share (Unadj.) Rs33.005.00 660.0%  
Dividend yield (eoy) %0.70.5 163.6%  
Book value per share (Unadj.) Rs868.8300.3 289.3%  
Shares outstanding (eoy) m23.03452.08 5.1%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.13.1 130.4%   
Avg P/E ratio x31.2197.2 15.8%  
P/CF ratio (eoy) x23.837.1 64.2%  
Price / Book Value ratio x5.13.6 139.5%  
Dividend payout %23.390.0 25.9%   
Avg Mkt Cap Rs m101,862495,502 20.6%   
No. of employees `0003.217.0 19.0%   
Total wages/salary Rs m3,68528,647 12.9%   
Avg. sales/employee Rs Th7,691.99,273.6 82.9%   
Avg. wages/employee Rs Th1,137.71,681.0 67.7%   
Avg. net profit/employee Rs Th1,006.5147.4 682.7%   
INCOME DATA
Net Sales Rs m24,914158,042 15.8%  
Other income Rs m8071,504 53.7%   
Total revenues Rs m25,721159,545 16.1%   
Gross profit Rs m5,37231,475 17.1%  
Depreciation Rs m1,02210,859 9.4%   
Interest Rs m112,044 0.5%   
Profit before tax Rs m5,14620,076 25.6%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,8862,885 65.4%   
Profit after tax Rs m3,2602,513 129.7%  
Gross profit margin %21.619.9 108.3%  
Effective tax rate %36.614.4 255.1%   
Net profit margin %13.11.6 823.0%  
BALANCE SHEET DATA
Current assets Rs m14,432122,095 11.8%   
Current liabilities Rs m6,01050,956 11.8%   
Net working cap to sales %33.845.0 75.1%  
Current ratio x2.42.4 100.2%  
Inventory Days Days6185 72.0%  
Debtors Days Days28120 23.8%  
Net fixed assets Rs m7,991129,876 6.2%   
Share capital Rs m230904 25.5%   
"Free" reserves Rs m19,778134,866 14.7%   
Net worth Rs m20,008135,771 14.7%   
Long term debt Rs m064,245 0.0%   
Total assets Rs m27,770263,054 10.6%  
Interest coverage x468.810.8 4,331.1%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.6 149.3%   
Return on assets %11.81.7 680.1%  
Return on equity %16.31.9 880.4%  
Return on capital %25.83.7 692.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,30653,141 11.9%   
Fx outflow Rs m5,25719,335 27.2%   
Net fx Rs m1,04933,807 3.1%   
CASH FLOW
From Operations Rs m4,35117,512 24.8%  
From Investments Rs m-787-14,073 5.6%  
From Financial Activity Rs m-1,884-14,921 12.6%  
Net Cashflow Rs m1,680-11,482 -14.6%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 60.4 0.2 30,200.0%  
Indian inst/Mut Fund % 14.4 11.3 127.4%  
FIIs % 14.6 31.9 45.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   15,184 98,259 15.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ORCHID PHARMA LTD  WYETH LTD  ASTRAZENECA PHARMA  SUVEN LIFE  CIPLA  

Compare SANOFI INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 12, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - PLETHICO PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS